IRLAB A — IRLAB Therapeutics AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK197.06m
- SEK116.73m
- SEK94.63m
Annual cashflow statement for IRLAB Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -91.5 | 52.6 | -113 | -181 | -75.1 |
| Depreciation | |||||
| Non-Cash Items | 2.06 | 41.8 | 4.48 | 7.24 | -4.06 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.182 | 34.3 | -34 | 8.67 | 9 |
| Change in Accounts Receivable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -89.2 | 129 | -143 | -165 | -65.6 |
| Capital Expenditures | -0.394 | -0.708 | -2.88 | -0.293 | -0.199 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -0.5 | 0 | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | -0.394 | -0.708 | -3.38 | -0.293 | -0.199 |
| Financing Cash Flow Items | 0.001 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 256 | -3.04 | -3.13 | 23.7 | 21.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 166 | 125 | -149 | -141 | -44.4 |